Scientists have announced the observation of “CP violation in a D meson” at CERN, a discovery that will appear in physics textbooks for years to come. You’re probably wondering what exactly it means.
The Universe is full of regular matter. There’s also antimatter, which exists even here on Earth, but there’s much less of it. This new observation is important on its own, but it also takes physicists another step closer to explaining where all the antimatter has disappeared to.
Turns out the key to making things lighter than air is…light!
California scientists think they’ve found a way to make objects levitate using concentrated light — a theory that could even propel spacecraft farther than they’ve ever traveled before, according to a report.
Researchers at the California Institute of Technology believe that by covering the surfaces of objects with microscopic nanoscale patterns specially designed to interact with beams of light, they could be propelled without fuel — and potentially by light sources millions of miles away, according to Phys.org.
A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine. The research, led by Wyss Institute Core Faculty member David Mooney, Ph.D., lays the foundation for a host of clinical applications in restorative dentistry and regenerative medicine more broadly, such as wound healing, bone regeneration, and more.
Posted in futurism
Chemistry researchers at Oregon State University have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
The synthesis of cephalotaxine and homoharringtonine (HHT) paves the way toward less-expensive, more readily available leukemia drugs whose production is not subject to the risks and inefficiencies associated with harvesting natural sources.
Also, the synthesis of cephalotaxine opens the door to preparing other, structurally related compounds for evaluation as potential new cancer drugs.
Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union, New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights.
Joe Betts Lacroix of Y Combinator and Vium discusses the different ways in which entrepreneurs can focus on overcoming the diseases of aging, namely direct, indirect, and money-first approaches, and the strengths and weakness of each.
Joe was the primary technical founder of hardware/software startup OQO, which entered the Guinness Book of World Records for building the smallest fully featured PC. His experience spans from biotech research to electronics design. Very experienced in invention, prosecution and monetization of intellectual property, he has over 80 patents granted and pending in fields ranging from biophysics and safety systems to antennas, thermal systems, user interfaces, and analog electronics. He has written numerous peer-reviewed publications in fields such as biophysics, genetics, electronics, and robotics. Joe holds a Harvard A.B., an MIT S.M. and a Caltech research fellowship.
